Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836826 + Venetoclax in CLL
NCT03343678Phase 1Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of BI 836826 in chronic lymphocytic leukemia (CLL), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose Limiting Toxicities at 28 days. Planned start Jan 2018; status: withdrawn.
02
Drugs
BI 836826
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03343678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343678.